Acromegaly from ectopic growth hormone‐releasing hormone secretion by a malignant carcinoid tumor. Successful treatment with long‐acting somatostatin analogue SMS 201–995

Cancer

Volumn 61, Issue 2, 1988, Pages 221-226

  Barkan, Ariel L ^a   Shenker, Yoram ^a   Grekin, Roger J ^a   Vale, Wylie W ^b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; FLUOROURACIL; GROWTH HORMONE RELEASING FACTOR; OCTREOTIDE; SOMATOSTATIN DERIVATIVE; STREPTOZOCIN;

ACROMEGALY; CARCINOID; CASE REPORT; COMPLICATION; COMPUTER ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; METASTASIS; PRIORITY JOURNAL;

ACROMEGALY; ADULT; CASE REPORT; GROWTH HORMONE; HUMAN; INSULIN-LIKE GROWTH FACTOR I; MALE; OCTREOTIDE; PITUITARY NEOPLASMS; RADIOIMMUNOASSAY; SOMATOSTATIN; SOMATOTROPIN-RELEASING HORMONE; SUPPORT, U.S. GOV'T, NON-P.H.S.; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0023865612     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/1097-0142(19880115)61:2<221::AID-CNCR2820610203>3.0.CO;2-3     Document Type: Article

References (27)

1. Somatotroph hyperplasia: Successful treatment of acromegaly by removal of a pancreatic islet tumor secreting a growth hormone‐releasing factor
2. Acromegaly due to production of a growth hormone releasing factor by a bronchial carcinoid tumor
3. Acromegaly and Cushing's syndrome associated with a foregut carcinoid syndrome
4. Growth hormone secretion dynamics in a patient with ectopic growth hormone‐releasing factor production
5. Reduction of pituitary size by the somatostatin analogue SMS 201–995 in a patient with an islet cell tumor secreting growth hormone releasing factor
6. Neue aspekte in der pathogenese der akromegalie‐somatolibrinome
7. SMS 201–995: A very potent and selective analogue of somatostatin with prolonged action
8. Endocrine profile of a long‐acting somatostatin derivative SMS 201–995: Study in normal volunteers following subcutaneous administration
9. Long‐term treatment of acromegaly with the somatostatin analogue SMS 201–995
10. Treatment of the malignant carcinoid tumor: Evaluation of a long‐acting somatostatin analogue
11. Treatment of inoperable glucagonoma with the long‐acting somatostatin analogue SMS 201–995
12. Malignant insulinoma: Effect of a somatostatin analog (compound 201–995) on serum glucose, growth, and gastro‐enteropancreatic hormones
13. Pancreatic cholera syndrome: Effect of a synthetic somatostatin analog on intestingal water and ion transport
14. Long‐term treatment of a VIPoma with somatostatin analogue resulting in remission of symptoms and possible shrinkage of metastases
15. Treatment of metastatic GRF‐producing tumor with a long‐acting somatostatin analogue
16. Pituitary and ectopic GRF mediated acromegaly treated with somatostatin analog SMS 201–995 (Abstr)
17. Acromegaly due to ectopic growth hormone (GH)‐releasing hormone (GHRH) production: Dynamic studies of GH and ectopic GHRH secretin
18. Estimation of somatomedin C levels in normals and patients with pituitary diseases by radioimmunoassay
19. Human pancreatic growth hormone‐releasing factor‐40 (hpGRF‐40) allows stimulation of GH release by TRH
20. Growth hormone‐releasing factor stimulates proliferation of somatotrophs in vitro
21. Inhibition of growth of the transplantable rat chondrosarcoma by analogs of hypothalamic hormones
22. Inhibition of growth of pancreatic carcinoma in animal models by analogs of hypothalamic hormones
23. Inhibition of growth of a prolactin‐secreting tumor in rats by analogs of luteinizing hormone‐releasing hormone and somatostatin
24. A somatostatin analogue inhibits chondrosarcoma and insulinoma tumor growth
25. Bombesin‐like peptides can function as autocrine growth factors in human small‐cell lung cancer
26. Patterns of growth hormone‐releasing factor and somatostatin secretion into the hypophysial‐portal circulation of the rat